Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population

Chérrez-Ojeda, Iván; Cortés-Télles, Arturo; Gochicoa‐Rangel, Laura; Camacho-Leon, Génesis; Mautong, Hans; Robles‐Velasco, Karla; Faytong-Haro, Marco

doi:10.3390/jpm12091393

Cited by 5 publications

(9 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the similarity in the effects observed across various questions, our results could potentially be applied to Ecuador’s neighboring countries in Latin America. This region, deeply impacted by the pandemic, grapples with diverse healthcare inequalities [ 6 , 19 , 21 , 29 ]. Our findings remain significant as they underscore the influence of brief video interventions on the social behavior of a population segment, reinforcing the potential of such interventions [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

The influence of a quick educational video intervention on COVID-19-related knowledge in Ecuador

Faytong-Haro,

Camacho-Leon,

Páez-Plúas

et al. 2023

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background: Coronavirus disease (COVID-19) is a pandemic that has spread worldwide. Since its discovery, health measures have been put in place to help stop it from spreading. Proper education about COVID-19 is important because it helps people to follow health control measures and learn more about the disease. Objective: This study aimed to compare people´s knowledge of COVID-19 before and after a brief video-based educational intervention. Methods: 87 participants in Ecuador were recruited from a dataset of COVID-positive patients in Ecuador between December 2021 and February 2022. This was a cross-sectional, pre- and post-intervention study. First, COVID-19 knowledge was evaluated and then an educational intervention was provided as a video. After the intervention, the same knowledge questions were used to test the participants, and marginal homogeneity-based chi-square tests were employed for comparison. Results: After watching the educational video, participants knew more about the age group most likely to get the disease and their knowledge of how long it takes for Covid to spread. Their knowledge of other aspects of COVID-19 has also increased. Conclusion: This study shows that educational intervention positively affects the knowledge of people who watch it. At the end of the study, after the intervention, the study participants knew more than they had before. This could be a useful tool for identifying possible pandemics.

show abstract

Section: Discussionmentioning

confidence: 99%

The influence of a quick educational video intervention on COVID-19-related knowledge in Ecuador

Faytong-Haro,

Camacho-Leon,

Páez-Plúas

et al. 2023

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…The investigators conducted an observational study in a cohort of persistently symptomatic patients, where a significant proportion was identified as having Post-SARS-CoV-2 ILD with both radiological abnormalities and ongoing physiological and functional deficit. Six weeks after discharge from hospital, following a structured assessment, patients who met the eligibility criteria were treated at a maximum initial dose of 0.5 mg/kg prednisolone/day (the average starting dose was Kumar et al 2021;Bazdyrev et al 2021;Cherrez-Ojeda et al 2022;Mohammadi et al 2022;Wu et al 2020;Zheng et al 2023).…”

Section: Corticosteroidsmentioning

confidence: 99%

“…Innovative and repurposed medications in research for pharmacological treatment of Post-COVID-19 pulmonary fibrosis(Echeverría-Esnal et al, 2021;Kumar et al 2021;Bazdyrev et al 2021;Cherrez-Ojeda et al 2022;Mohammadi et al 2022;Wu et al 2020;Zheng et al 2023). …”

mentioning

confidence: 99%

Pharmacological approaches to pulmonary fibrosis following COVID-19

et al. 2023

View full text Add to dashboard Cite

Background: In the past few years, COVID-19 became the leading cause of morbidity and mortality worldwide. Although the World Health Organization has declared an end to COVID-19 as a public health emergency, it can be expected, that the emerging new cases at the top of previous ones will result in an increasing number of patients with post-COVID-19 sequelae. Despite the fact that the majority of patients recover, severe acute lung tissue injury can in susceptible individuals progress to interstitial pulmonary involvement. Our goal is to provide an overview of various aspects associated with the Post-COVID-19 pulmonary fibrosis with a focus on its potential pharmacological treatment options.Areas covered: We discuss epidemiology, underlying pathobiological mechanisms, and possible risk and predictive factors that were found to be associated with the development of fibrotic lung tissue remodelling. Several pharmacotherapeutic approaches are currently being applied and include anti-fibrotic drugs, prolonged use or pulses of systemic corticosteroids and non-steroidal anti-inflammatory and immunosuppressive drugs. In addition, several repurposed or novel compounds are being investigated. Fortunately, clinical trials focused on pharmacological treatment regimens for post-COVID-19 pulmonary fibrosis have been either designed, completed or are already in progress. However, the results are contrasting so far. High quality randomised clinical trials are urgently needed with respect to the heterogeneity of disease behaviour, patient characteristics and treatable traits.Conclusion: The Post-COVID-19 pulmonary fibrosis contributes to the burden of chronic respiratory consequences among survivors. Currently available pharmacotherapeutic approaches mostly comprise repurposed drugs with a proven efficacy and safety profile, namely, corticosteroids, immunosuppressants and antifibrotics. The role of nintedanib and pirfenidone is promising in this area. However, we still need to verify conditions under which the potential to prevent, slow or stop progression of lung damage will be fulfilled.

show abstract

“…Post-acute COVID-19 syndrome (PACS) afflicts more than half of patients two years after the acute phase, placing a significant burden on individuals and the healthcare system [ 1 ]. Conventional pulmonary function tests (PFTs) and imaging studies, such as computed tomography (CT) scans, are used to follow up post-acute COVID-19 patients [ 2 ]. However, small airway disease (SAD), as a potential cause of persistent clinical symptoms and imaging abnormalities, has received little attention [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Small airway disease in post-acute COVID-19 syndrome, a non-conventional approach in three years follow-up of a patient with long COVID: a case report

Cherrez-Ojeda,

Osorio,

Robles-Velasco

et al. 2023

J Med Case Reports

Self Cite

View full text Add to dashboard Cite

Background Small airways disease (SAD), a novel finding described in post-acute COVID-19 patients, should be suspected when respiratory symptoms continue, air trapping persists on expiratory CT scans, and imaging findings fail to improve despite objectively better conventional pulmonary function test (PFT) parameters. The forced oscillation technique (FOT) and Multiple breathing washout (MBW) are both very sensitive methods for detecting anomalies in the peripheral airways. Case presentation We discuss the case of a 60-year-old Hispanic patient who had severe COVID-19 pneumonia and developed dyspnea, fatigue, and limited daily activity a year later. The PFTs revealed restrictive lung disease, as seen by significant diffusing capacity of the lungs for carbon monoxide (DLCO) decrease, severe desaturation, and poor 6-min walk test (6MWT) performance. The patient was treated with lowering corticosteroids as well as pulmonary rehabilitation (PR). During the 24-month follow-up, the dyspnea and fatigue persisted. On PFTs, 6MWT performance and restricted pattern improved slightly, but MBW discovered significant ventilatory inhomogeneity. FOT revealed substantial peripheral airway obstructive abnormalities. On CT scans, air trapping and ground-glass opacities (GGO) improved somewhat. The patient used a bronchodilator twice a day and low-dose inhaled corticosteroids (160 µg of budesonide and 4.5 µg of formoterol fumarate dihydrate) for nine months. PR sessions were resuming. The restricting parameters were stabilized and the DLCO had normalized after 36 months, with a 6MWT performance of 87% but significant desaturation. The CT scan revealed traction bronchiectasis, low GGO, and persistent air trapping. Without normalization, FOT and MBW scores improved, indicating small airway disease. Conclusions The necessity of integrating these tests when detecting SAD is emphasized in our paper. This article lays the foundation for future research into the best ways to manage and monitor SAD in post-acute COVID-19 patients.

show abstract

Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population

Cited by 5 publications

References 86 publications

The influence of a quick educational video intervention on COVID-19-related knowledge in Ecuador

The influence of a quick educational video intervention on COVID-19-related knowledge in Ecuador

Pharmacological approaches to pulmonary fibrosis following COVID-19

Small airway disease in post-acute COVID-19 syndrome, a non-conventional approach in three years follow-up of a patient with long COVID: a case report

Contact Info

Product

Resources

About